Applicability of Monoclonal Antibodies Against Estrogen and Progesterone Receptors in the Immunocytochemical Evaluation of Breast Carcinomas
The development of monoclonal antibodies against receptor proteins for estrogen (ER) and progesterone (PR) has opened a new perspective in the endocrinological evaluation of breast cancer patients. Indeed, a great deal of information can be obtained by applying these antibodies to tissue sections, including information that cannot be provided by steroid-binding assays. Of particular interest is the assessment of the percentage of receptor-positive cells in any given tumor, which can be easily evaluated in stained sections, but cannot be estimated by biochemical assays on tissue homogenates. Basic research in this field has been done on frozen sections which have proved to be quite reliable as documented by several reports presented at a recent symposium on Estrogen Receptor Determination with Monoclonal Antibodies (Cancer Res. Suppl. 46: 4231–4314, 1986). However, for the purpose of using immunocytochemistry for the practical assessment of the ER and PR status of breast cancer patients it should be realized that tissue for frozen sections is not always available and for this reason it is important to be able to apply these techniques to paraffin embedded tissues or to cytological preparations.
KeywordsFreeze Section Paraffin Section Positive Nucleus Infiltrate Ductal Carcinoma H222 Antibody
Unable to display preview. Download preview PDF.
- 4.L. S. Miller, I. I. E. Tribby, M. R. Miles, J. T. Tomita, and C. Nolan,Hybridomas producing monoclonal antibodies to human estrogen receptor, Fed. Proc. 41: 520 (1980).Google Scholar
- 5.L. Ozzello, C. M. DeRosa, J. G. Konrath, J. L. Yeager and L. S. Miller,Detection of estrophilin in frozen sections of breast cancers using an estrogen receptor immunocytochemical assay. Cancer Res. 46: 4303 (1986).Google Scholar
- 8.L. Ozzello, C. DeRosa, D. V. Habif, and R. Lipton, Immunostaining of estrogen receptors in paraffin sections of breast cancers using anti-estrophilin monoclonal antibodies, in: “Monoclonal Antibodies and Breast Cancer,” R. L. Ceriani, ed., Martinus Nijhoff Publishing, Boston (1985).Google Scholar
- 9.A. Shimada, S. Kimura, K. Abe, K. Nagasaki, J. Adachi, K. Yamaguchi,M. Suzuki, T. Nakajima, and L. S. Miller, Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: Comparison with that in frozen sections, Proc. Natl. Acad. Sci. USA 82: 4803 (1985).PubMedCrossRefGoogle Scholar